Standard BioTools
LAB
145 hedge funds and large institutions have $308M invested in Standard BioTools in 2025 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 42 reducing their positions, and 16 closing their positions.
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
2% more funds holding
Funds holding: 142 → 145 (+3)
0.38% more ownership
Funds ownership: 74.78% → 75.16% (+0.38%)
7% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 42
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $487M → $308M (-$179M)
90% less call options, than puts
Call options by funds: $6K | Put options by funds: $62K
Top Buyers
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$9.41M |
| 2 |
CC
Casdin Capital
New York
|
+$6.77M |
| 3 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
+$4.79M |
| 4 |
MCO
MAK Capital One
New York
|
+$3.9M |
| 5 |
PCP
Pacific Capital Partners
London,
|
+$807K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$8.62M |
| 2 |
KLP
Kent Lake PR
Anasco,
Puerto Rico
|
-$3.73M |
| 3 |
Millennium Management
New York
|
-$2.82M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$911K |
| 5 |
Goldman Sachs
New York
|
-$698K |
LAB Hedge Fund Activity: Q1 2025 in Review
145 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2025, worth a combined $308M — down 37% from $487M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LAB positions and 16 closed out — a net gain of 5 holders — while 39 added to existing stakes and 42 trimmed.
The largest buyer was Long Focus Capital Management, opening a new position worth an estimated $9.41M. The largest seller was Morgan Stanley, cutting an estimated $8.62M.
- 145 institutional investors held Standard BioTools (LAB) as of Q1 2025, up from 142 in Q4 2024.
- Funds reported $308M of Standard BioTools stock for Q1 2025, down 37% quarter-over-quarter.
- 21 funds opened new Standard BioTools positions in Q1 2025 and 16 closed out, a net change of +5 holders.
- The largest Standard BioTools buyer in Q1 2025 was Long Focus Capital Management, an estimated $9.41M added.
- The largest Standard BioTools seller in Q1 2025 was Morgan Stanley, an estimated $8.62M sold.
Based on aggregated 13F filings for Q1 2025.